The integration of chemotherapy and surgery for bladder cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 1, 2005, Pages 45-51

  Galsky, Matthew D ^a,b   Herr, Harry W ^a,b   Bajorin, Dean F ^a,b,c  

^a Memorial Sloan Kettering Cancer Center ^*

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant chemotherapy; Bladder cancer; Lymphadenectomy; Neoadjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PATIENT CARE; PELVIS LYMPHADENECTOMY; REVIEW; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 33745010018     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0003     Document Type: Review

References (33)

1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
2. Vieweg J, Gschwend JE, Herr HW, et al. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449-454.
3. Viewig J, Whitmore WF, Herr H, et al. The role of pelvic lympadenectomy and radical cystectomy for lymph node positive bladder cancer: The Memorial Sloan-Kettering Cancer Center experience. Cancer 1994;73:3020-3028.
4. Herr HW: Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality). BJU Int 2003;92:187-188.
5. Herr HW: Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003;61:105-108.
6. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003;169:946-950.
7. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: A cooperative group report. J Clin Oncol 2004;22:2781-2789.
8. Herr H, Lee C, Chang S, et al. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer A collaborative group report. J Urol 2004;171:1823-8; discussion 1827-828.
9. Bajorin DF: Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Clin Oncol 2001;19:17S-20S.
10. Splinter TA, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol 1992;147:606-608.
11. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988;139:470-474.
12. Bassi P, Pagano F, Pappagallo G, et al. Neo-adjuvant M-VAC of invasive bladder cancer: G.U.O.N.E. multicenter phase III trial (Abstr #567). Eur Urol 1998;33:142.
13. Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991;67:608-615.
14. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 1995;153:964-973.
15. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-3583.
16. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: A prospective randomized clinical trial (Abstr #623). Proc Am Soc Clin Oncol 1995;14:237.
17. Hall R. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer (Abstr #710). Proc Am Soc Clin Oncul 2002;21:178a.
18. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 2003;349:859-866.
19. Malmstrom PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155:1903-1906.
20. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003;561:1927-1934.
21. Bono AV, Benvenuti C, Reali L, et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Rus 1989;303:533-540.
22. Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302-306; discussion 306-307.
23. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-464; discussion 464-467.
24. Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer results of a prospective randomized trial. J Urol 1994;152:81-84.
25. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-499; discussion 499-500.
26. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001;19:4005-4013.
27. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 200;18:3068-3077.
28. Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999;17:2546-2552.
29. Donat SM, Herr HW, Bajorin DF, et al. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 1996;156:368-371.
30. Miller R, Freiha F, Reese J, et al. Surgical restaging of patients with advanced transitional cell carcinoma of the urothelium treated with cisplatin, methotrexate, and vinblastine: Update of the Stanford University experience (Abstr). Proc Am Soc Clin Oncol 1992;10:167.
31. Herr HW, Donat SM, Bajorin DF: Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165:811-814.
32. Malmstrom PU, Rintala E, Wahlqvist R, et al. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer: Nordic cystectomy trial 2: XIVth Congress of the European Association of Urology (Abstr #238). Eur Urol 1999;35(Suppl 2):60.
33. Abol-Enein H, El-Mekresh M, El-Baz M, et al. Neoadjuvant chemotherapy in treatment of invasive transitional bladder cancer: A controlled prospective randomized study (Abstr #191). Br J Urol 1997;80(Suppl 2):49.